To Determine the Ability of a New Product Formulation to Remineralize an Early Caries Lesion by an In-situ Study

• Status: Unknown status
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a double blind, cross-over, controlled clinical trial utilizing thirty (30) adults to evaluate remineralization of early caries lesions.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Colgate Palmolive
• Treatments: Fluorides

Criteria

Inclusion Criteria:

1. Male and/or female subjects 18 to 50 years inclusive

2. Minimum of 20 natural uncrowned teeth (excluding third molars) must be present

3. Willing to wear retainer 24 hours per day

4. No active, unrestored cavities

5. Have normal salivary flow rate (stimulated and unstimulated flow of ≥0.7 ml/min and ≥ 0.2 ml/min respectively) ascertained from a preliminary sialometry

6. Available throughout entire study

7. Willing to use only assigned products for oral hygiene throughout the duration of the study

8. Must give written informed consent

9. Must be in good general health

10. No known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study

Exclusion Criteria:

1. Advanced periodontal disease

2. Medical condition which requires premedication prior to dental visits/procedures

3. Not enough teeth to secure the oral retainer

4. Diseases of the soft or hard oral tissues

5. Wear an Orthodontic appliances

6. Impaired salivary function

7. Current use drugs that can affect salivary flow

8. Use antibiotics one (1) month prior to or during this study

9. Pregnant or breastfeeding

10. Participate in another clinical study one (1) week prior to the start of the washout period or during this 9-week study period

11. Use tobacco products

12. Allergic to common toothpaste ingredients

13. Allergic to amino acids

14. Immune compromised individuals (HIV, AIDS, immuno-suppressive drug therapy)